Additionally, PD-1 knockout has demonstrated increased anti-tumor activity in CD19 CAR-T cells for hematological malignancies, GPC3 CAR-T cells for liver cancer, and mesothelin CAR-T cells for human ductal adenocarcinoma. This evidence concerns the gene PDCD1 and neoplasm.